Короткий опис (реферат):
Hypothyroidism affects metabolism and can be an important factor in the development of metabolic disorders. Metabolic-associated fatty liver disease (MASLD) and obesity occupy a special place in clinical practice due to the high risk of progression to cirrhosis and cardiovascular complications. Recent data suggest that intestinal dysbiosis may act as a key mediator in the pathogenesis of these conditions. This article reviews the pathogenetic mechanisms of the interaction of hypothyroidism, MASLD and obesity, as well as the role of microbiota as a potential target for therapeutic intervention, in particular with the help of probiotics and other corrective measures.